Global Intranasal Drug Delivery Devices Market by Product (Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-dose Inhalers, and Others), By Dosage (Unit-dose and Multi-dose) By Application (Respiratory Disorders, Neurological Disorder, Vaccination, Pain Management and Others), By End-user (Personal Use, Hospitals/Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 - 2028
Intranasal Drug Delivery Devices Market Outlook
The global intranasal drug delivery devices market was valued at USD 4,061.4 Mn in 2020 and is expected to reach USD 6,601.7 Mn by 2028, expanding at a CAGR of 6.5% during the forecast period. Nasal administration has been used for therapeutic purposes for centuries. The respiratory tract is a primary contact area for the environment and it represents a gateway for potential treatments and infectious particles such as viruses & bacteria. Intranasal administration is a non-invasive drug route of administration, widely used for the local treatment of nasal polyposis or rhinitis.
In order to obtain effective and safe intranasal pharmaceutical products, a large number of strategies is applied to overcome nasal release barriers. In the design of a nasal product, three main cooperative entities must be considered: the administration device, the drug, and the delivery carrier. Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration.
This is attributed to the large surface area, porous endothelial membrane, high total blood flow, avoidance of first-pass metabolism, and ready accessibility. The nasal administration of drugs, including numerous compounds, peptide and protein drugs, for systemic medication has been widely investigated in recent years. Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption.
Scope of Intranasal Drug Delivery Devices Market Report
The report on the global Intranasal Drug Delivery Devices Market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes |
Details |
Report Title |
Intranasal Drug Delivery Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Product (Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-dose Inhalers, and Others), Dosage (Unit-dose and Multi-dose) Application (Respiratory Disorders, Neurological Disorder, Vaccination, Pain Management and Others), End-user (Personal Use, Hospitals/Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered |
Teleflex Incorporated, AptarGroup, Inc., Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Vectura Group plc, Recipharm AB, H&T Presspart Manufacturing Ltd, Nemera Development S.A., OptiNose Inc, and Others. |
Intranasal Drug Delivery Devices Market Dynamics
Increasing Prevalence of Chronic Disease
Demand for nasal sprays is growing, owing to the increasing prevalence of chronic diseases, such as cardiovascular diseases (CVDs), nasal congestion, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease (COPD), and diabetes. This is expected to propel the intranasal drug delivery devices market during the forecast period.
Topical forms of medical therapy represent an attractive alternative for the administration of drugs into the paranasal sinuses and nasal cavity. The increasing incidence of chronic diseases is projected to contribute to the expansion of the intranasal drug delivery devices market over the coming years.
Introduction of Off-patent Drugs for Respiratory Care to Reconcile the Supply of MDIs and DPIs
The expiration of the patent for branded inhaled drugs and increasing pressure on the healthcare budget are leading to the development of generic inhaled drugs. As the cost of treating asthma and COPD decreases, awareness and the adoption of MDI & DPI are likely to increase among patients. Companies are focusing on the development of low-cost drugs to provide cost-effective treatment.
For instance, in February 2019, the US Food and Drug Administration (FDA) approved Mylan’s generic version of Advair Diskus of GlaxoSmithKline. The generic drug (Wixela Inhub) is intended for the treatment of asthma and COPD patients and was launched at a lower price than the brand. Additionally, increased patient awareness of the benefits of using MDI and DPI are expected to propel the market over the coming years.
Restraints
Rising Complications associated with the overuse of nasal sprays
Sprays are easy to access for patients, hence most people mistakenly presume that nasal sprays are safe to use and are unaware of the potential addiction or possible side effects. Rhinitis Medicamentosa (RM) refers to the nasal inflammation caused by the use of medications. It is common for patients who regularly use nasal sprays to abuse the drug.
Continuous use of nasal sprays leads to down-regulation of the receptors on the blood vessel in the nose, which methat the number of receptors decreases, and when the user stops taking the drug, a rebound effect of nasal inflammation occurs. Atrophy of the nasal mucosa is a common drawback associated with rhinitis medicamentosa. This includes scars of the nose coating, which causes symptoms such as bleeding, dry nose, and irritation.
Difficulty in delivering the drug to the olfactory region of the human nasal cavity
Drug delivery devices have been found to play an important role in ensuring that all of the drugs are delivered to the target site in the nasal cavity. It is difficult to accurately deliver the drug to the olfactory region of the human nasal cavity, as this region is located high in the nasal cavity, above the upper concha. This area is exposed to a low volume of air entering the nasal cavity and leads to low doses of the drug reaching the olfactory region. This in turn, is expected to impede the growth of the intranasal drug delivery devices market during the forecast period.
Opportunity
Increasing R&D Activities
Innovative strategic approaches to design efficient nasal delivery systems for specific drugs are currently in various stages of research and development. These include the design of barriers that prevent the degradation of drugs by mucosal enzymes, sophisticated devices for targeted drug delivery to the brain, new and improved nasal delivery technologies, and the modulation of physicochemical properties of the vectors. This in turn, is anticipated to provide various lucrative growth opportunities during the forecast period.
Intranasal Drug Delivery Devices Market Segmental Outlook
The intranasal drug delivery devices market is segmented into products, dosage, applications, end-users, distribution channels, and regions.
On the basis of products, the global intranasal drug delivery devices market is segmented into powder delivery device, liquid delivery device, pressurized metered-dose inhalers, and others. The liquid delivery device segment held a significant market share and is anticipated to grow in the coming years. Liquid delivery devices are considered convenient, particularly for topical indications where humidification counteracts the dryness and crusting often accompanying chronic nasal diseases.
Based on dosage, the global intranasal drug delivery devices market is segmented into unit-dose and multi-dose. The unit-dose segment held a significant market share and is anticipated to grow in the coming years. A unit-dose device is for single-use, pre-filled, already-assembled, disposable products such as IMITREX (sumatriptan nasal spray) and NARCAN (naloxone nasal spray). It is ideal for urgent treatments.
In terms of applications, the global intranasal drug delivery devices market is segmented into respiratory disorders, neurological disorders, vaccination, pain management, and others. The increasing prevalence of respiratory disorders such as asthma and COPD among people is expected to propel the global intranasal drug delivery devices market in the coming years.
On the basis of end-users, the global intranasal drug delivery devices market is segmented into personal use, hospitals/clinics, and others. The personal use segment is expected to hold a significant market share during the forecast period, owing to increasing patient preference for self-administrated drugs and the growing usage of nasal sprays and powders that are easily administered by patients. Furthermore, the self-administration of drugs in home care settings helps patients save money and time, which in turn, brings down healthcare costs incurred by the patient.
Based on distribution channels, the global intranasal drug delivery devices market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant market share and is anticipated to grow in the coming years, owing to increasing focus on positive medical outcomes, patient awareness, and self-administration.
Intranasal Drug Delivery Devices Market Regional Outlook
On the basis of regions, the global intranasal drug delivery devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing government (U.S. FDA) approval for the use of the intranasal drug delivery devices such as nasal sprays and nasal powder.
The market in Europe is expected to grow at a rapid pace during the forecast period, due to the presence of large number of players in the region. The market in Asia Pacific is projected to hold considerable market share during the forecast period, owing to increasing R&D activities in countries such as China.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Intranasal Drug Delivery Devices market
- Historical, Current and Projected Market Size in terms of Value and Volume
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Intranasal Drug Delivery Devices Market Performance
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intranasal Drug Delivery Devices Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Intranasal Drug Delivery Devices Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Intranasal Drug Delivery Devices Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Intranasal Drug Delivery Devices Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Intranasal Drug Delivery Devices Market Size & Forecast, 2018-2028
4.5.1 Intranasal Drug Delivery Devices Market Size and Y-o-Y Growth
4.5.2 Intranasal Drug Delivery Devices Market Absolute $ Opportunity
4.6 Suppliers and their Offerings Outlook
4.7 Preservative Free Pump Technology Suppliers Overview
4.8 Unidose and Bidose Intranasal Delivery Systems Suppliers Outlook
4.9 Pipeline Analysis
4.10 Intranasal Nebuliser Systems Outlook
Chapter 5 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Product
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Product
5.1.2 Basis Point Share (BPS) Analysis By Product
5.1.3 Absolute $ Opportunity Assessment By Product
5.2 Intranasal Drug Delivery Devices Market Size Forecast By Product
5.2.1 Powder Delivery Devic
5.2.2 Liquid Delivery Device
5.2.3 Pressurized Metered-dose
5.2.4 Inhalers
5.2.5 Others
5.3 Market Attractiveness Analysis By Product
Chapter 6 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Dosage
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Dosage
6.1.2 Basis Point Share (BPS) Analysis By Dosage
6.1.3 Absolute $ Opportunity Assessment By Dosage
6.2 Intranasal Drug Delivery Devices Market Size Forecast By Dosage
6.2.1 Unit-dose
6.2.2 Multi-dose
6.3 Market Attractiveness Analysis By Dosage
Chapter 7 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Intranasal Drug Delivery Devices Market Size Forecast By Application
7.2.1 Respiratory Disorders
7.2.2 Neurological Disorder
7.2.3 Vaccination
7.2.4 Pain Management
7.2.5 Others
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By End-user
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-user
8.1.2 Basis Point Share (BPS) Analysis By End-user
8.1.3 Absolute $ Opportunity Assessment By End-user
8.2 Intranasal Drug Delivery Devices Market Size Forecast By End-user
8.2.1 Personal Use
8.2.2 Hospitals/Clinics
8.2.3 Others
8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Intranasal Drug Delivery Devices Market Analysis and Forecast By Distribution Channel
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Distribution Channel
9.1.2 Basis Point Share (BPS) Analysis By Distribution Channel
9.1.3 Absolute $ Opportunity Assessment By Distribution Channel
9.2 Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
9.2.1 Hospital Pharmacies
9.2.2 Retail Pharmacies
9.2.3 Online Pharmacies
9.3 Market Attractiveness Analysis By Distribution Channel
Chapter 10 Global Intranasal Drug Delivery Devices Market Analysis and Forecast by Region
10.1 Introduction
10.1.1 Key Market Trends & Growth Opportunities by Region
10.1.2 Basis Point Share (BPS) Analysis by Region
10.1.3 Absolute $ Opportunity Assessment by Region
10.2 Intranasal Drug Delivery Devices Market Size Forecast by Region
10.2.1 North America
10.2.2 Europe
10.2.3 Asia Pacific
10.2.4 Latin America
10.2.5 Middle East & Africa (MEA)
10.3 Market Attractiveness Analysis by Region
Chapter 11 Coronavirus Disease (COVID-19) Impact
11.1 Introduction
11.2 Current & Future Impact Analysis
11.3 Economic Impact Analysis
11.4 Government Policies
11.5 Investment Scenario
Chapter 12 North America Intranasal Drug Delivery Devices Analysis and Forecast
12.1 Introduction
12.2 North America Intranasal Drug Delivery Devices Market Size Forecast by Country
12.2.1 U.S.
12.2.2 Canada
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 North America Intranasal Drug Delivery Devices Market Size Forecast By Product
12.6.1 Powder Delivery Devic
12.6.2 Liquid Delivery Device
12.6.3 Pressurized Metered-dose
12.6.4 Inhalers
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis By Product
12.8 Absolute $ Opportunity Assessment By Product
12.9 Market Attractiveness Analysis By Product
12.10 North America Intranasal Drug Delivery Devices Market Size Forecast By Dosage
12.10.1 Unit-dose
12.10.2 Multi-dose
12.11 Basis Point Share (BPS) Analysis By Dosage
12.12 Absolute $ Opportunity Assessment By Dosage
12.13 Market Attractiveness Analysis By Dosage
12.14 North America Intranasal Drug Delivery Devices Market Size Forecast By Application
12.14.1 Respiratory Disorders
12.14.2 Neurological Disorder
12.14.3 Vaccination
12.14.4 Pain Management
12.14.5 Others
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 North America Intranasal Drug Delivery Devices Market Size Forecast By End-user
12.18.1 Personal Use
12.18.2 Hospitals/Clinics
12.18.3 Others
12.19 Basis Point Share (BPS) Analysis By End-user
12.20 Absolute $ Opportunity Assessment By End-user
12.21 Market Attractiveness Analysis By End-user
12.22 North America Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
12.22.1 Hospital Pharmacies
12.22.2 Retail Pharmacies
12.22.3 Online Pharmacies
12.23 Basis Point Share (BPS) Analysis By Distribution Channel
12.24 Absolute $ Opportunity Assessment By Distribution Channel
12.25 Market Attractiveness Analysis By Distribution Channel
Chapter 13 Europe Intranasal Drug Delivery Devices Analysis and Forecast
13.1 Introduction
13.2 Europe Intranasal Drug Delivery Devices Market Size Forecast by Country
13.2.1 Germany
13.2.2 France
13.2.3 Italy
13.2.4 U.K.
13.2.5 Spain
13.2.6 Russia
13.2.7 Rest of Europe
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Europe Intranasal Drug Delivery Devices Market Size Forecast By Product
13.6.1 Powder Delivery Devic
13.6.2 Liquid Delivery Device
13.6.3 Pressurized Metered-dose
13.6.4 Inhalers
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis By Product
13.8 Absolute $ Opportunity Assessment By Product
13.9 Market Attractiveness Analysis By Product
13.10 Europe Intranasal Drug Delivery Devices Market Size Forecast By Dosage
13.10.1 Unit-dose
13.10.2 Multi-dose
13.11 Basis Point Share (BPS) Analysis By Dosage
13.12 Absolute $ Opportunity Assessment By Dosage
13.13 Market Attractiveness Analysis By Dosage
13.14 Europe Intranasal Drug Delivery Devices Market Size Forecast By Application
13.14.1 Respiratory Disorders
13.14.2 Neurological Disorder
13.14.3 Vaccination
13.14.4 Pain Management
13.14.5 Others
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Europe Intranasal Drug Delivery Devices Market Size Forecast By End-user
13.18.1 Personal Use
13.18.2 Hospitals/Clinics
13.18.3 Others
13.19 Basis Point Share (BPS) Analysis By End-user
13.20 Absolute $ Opportunity Assessment By End-user
13.21 Market Attractiveness Analysis By End-user
13.22 Europe Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
13.22.1 Hospital Pharmacies
13.22.2 Retail Pharmacies
13.22.3 Online Pharmacies
13.23 Basis Point Share (BPS) Analysis By Distribution Channel
13.24 Absolute $ Opportunity Assessment By Distribution Channel
13.25 Market Attractiveness Analysis By Distribution Channel
Chapter 14 Asia Pacific Intranasal Drug Delivery Devices Analysis and Forecast
14.1 Introduction
14.2 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast by Country
14.2.1 China
14.2.2 Japan
14.2.3 South Korea
14.2.4 India
14.2.5 Australia
14.2.6 South East Asia (SEA)
14.2.7 Rest of Asia Pacific (APAC)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Product
14.6.1 Powder Delivery Devic
14.6.2 Liquid Delivery Device
14.6.3 Pressurized Metered-dose
14.6.4 Inhalers
14.6.5 Others
14.7 Basis Point Share (BPS) Analysis By Product
14.8 Absolute $ Opportunity Assessment By Product
14.9 Market Attractiveness Analysis By Product
14.10 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Dosage
14.10.1 Unit-dose
14.10.2 Multi-dose
14.11 Basis Point Share (BPS) Analysis By Dosage
14.12 Absolute $ Opportunity Assessment By Dosage
14.13 Market Attractiveness Analysis By Dosage
14.14 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Application
14.14.1 Respiratory Disorders
14.14.2 Neurological Disorder
14.14.3 Vaccination
14.14.4 Pain Management
14.14.5 Others
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By End-user
14.18.1 Personal Use
14.18.2 Hospitals/Clinics
14.18.3 Others
14.19 Basis Point Share (BPS) Analysis By End-user
14.20 Absolute $ Opportunity Assessment By End-user
14.21 Market Attractiveness Analysis By End-user
14.22 Asia Pacific Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
14.22.1 Hospital Pharmacies
14.22.2 Retail Pharmacies
14.22.3 Online Pharmacies
14.23 Basis Point Share (BPS) Analysis By Distribution Channel
14.24 Absolute $ Opportunity Assessment By Distribution Channel
14.25 Market Attractiveness Analysis By Distribution Channel
Chapter 15 Latin America Intranasal Drug Delivery Devices Analysis and Forecast
15.1 Introduction
15.2 Latin America Intranasal Drug Delivery Devices Market Size Forecast by Country
15.2.1 Brazil
15.2.2 Mexico
15.2.3 Rest of Latin America (LATAM)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Product
15.6.1 Powder Delivery Devic
15.6.2 Liquid Delivery Device
15.6.3 Pressurized Metered-dose
15.6.4 Inhalers
15.6.5 Others
15.7 Basis Point Share (BPS) Analysis By Product
15.8 Absolute $ Opportunity Assessment By Product
15.9 Market Attractiveness Analysis By Product
15.10 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Dosage
15.10.1 Unit-dose
15.10.2 Multi-dose
15.11 Basis Point Share (BPS) Analysis By Dosage
15.12 Absolute $ Opportunity Assessment By Dosage
15.13 Market Attractiveness Analysis By Dosage
15.14 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Application
15.14.1 Respiratory Disorders
15.14.2 Neurological Disorder
15.14.3 Vaccination
15.14.4 Pain Management
15.14.5 Others
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Latin America Intranasal Drug Delivery Devices Market Size Forecast By End-user
15.18.1 Personal Use
15.18.2 Hospitals/Clinics
15.18.3 Others
15.19 Basis Point Share (BPS) Analysis By End-user
15.20 Absolute $ Opportunity Assessment By End-user
15.21 Market Attractiveness Analysis By End-user
15.22 Latin America Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
15.22.1 Hospital Pharmacies
15.22.2 Retail Pharmacies
15.22.3 Online Pharmacies
15.23 Basis Point Share (BPS) Analysis By Distribution Channel
15.24 Absolute $ Opportunity Assessment By Distribution Channel
15.25 Market Attractiveness Analysis By Distribution Channel
Chapter 16 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Analysis and Forecast
16.1 Introduction
16.2 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast by Country
16.2.1 Saudi Arabia
16.2.2 South Africa
16.2.3 UAE
16.2.4 Rest of Middle East & Africa (MEA)
16.3 Basis Point Share (BPS) Analysis by Country
16.4 Absolute $ Opportunity Assessment by Country
16.5 Market Attractiveness Analysis by Country
16.6 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Product
16.6.1 Powder Delivery Devic
16.6.2 Liquid Delivery Device
16.6.3 Pressurized Metered-dose
16.6.4 Inhalers
16.6.5 Others
16.7 Basis Point Share (BPS) Analysis By Product
16.8 Absolute $ Opportunity Assessment By Product
16.9 Market Attractiveness Analysis By Product
16.10 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Dosage
16.10.1 Unit-dose
16.10.2 Multi-dose
16.11 Basis Point Share (BPS) Analysis By Dosage
16.12 Absolute $ Opportunity Assessment By Dosage
16.13 Market Attractiveness Analysis By Dosage
16.14 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Application
16.14.1 Respiratory Disorders
16.14.2 Neurological Disorder
16.14.3 Vaccination
16.14.4 Pain Management
16.14.5 Others
16.15 Basis Point Share (BPS) Analysis By Application
16.16 Absolute $ Opportunity Assessment By Application
16.17 Market Attractiveness Analysis By Application
16.18 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By End-user
16.18.1 Personal Use
16.18.2 Hospitals/Clinics
16.18.3 Others
16.19 Basis Point Share (BPS) Analysis By End-user
16.20 Absolute $ Opportunity Assessment By End-user
16.21 Market Attractiveness Analysis By End-user
16.22 Middle East & Africa (MEA) Intranasal Drug Delivery Devices Market Size Forecast By Distribution Channel
16.22.1 Hospital Pharmacies
16.22.2 Retail Pharmacies
16.22.3 Online Pharmacies
16.23 Basis Point Share (BPS) Analysis By Distribution Channel
16.24 Absolute $ Opportunity Assessment By Distribution Channel
16.25 Market Attractiveness Analysis By Distribution Channel
Chapter 17 Competition Landscape
17.1 Intranasal Drug Delivery Devices Market: Competitive Dashboard
17.2 Global Intranasal Drug Delivery Devices Market: Market Share Analysis, 2020
17.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
17.3.1 3M
17.3.2 AptarGroup, Inc.
17.3.3 BD
17.3.4 Eli Lilly and Company
17.3.5 GSK group
17.3.6 Heitkamp & Thumann Group
17.3.7 Johnson & Johnson Services, Inc
17.3.8 Nemera
17.3.9 Neurelis, Inc.
17.3.10 Recipharm AB (Bespak)
17.3.11 Teleflex Incorporated
17.3.12 Vectura Group plc